Back to Education Zone

touchCONGRESS Expert Forum

How do we optimize outcomes for patients with HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibition?

Introduction

Watch a group of leading breast cancer specialists debate and discuss how to optimize clinical outcomes for patients with advanced HR+/HER2- disease in the era of CDK4/6 inhibition.

Professor Nadia Harbeck (co-Chair; Germany), Professor Di Leo (co-Chair; Italy), Professor François-Clément Bidard (France) and Professor Valentina Guarneri (Italy) consider the available evidence for key topics of interest, addressing important clinical questions that are pertinent for daily practice.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

This touchCONGRESS Expert Forum was recorded during the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, 19–23 October 2018.

Learning Objectives

After watching this touchCONGRESS Expert Forum, you should:

 

  • Have an increased awareness of treatment sequencing and the optimal duration of therapies in patients with HR+/HER2- advanced breast cancer.
  • Be aware of whether prognostic and differentiation factors may drive the optimal use of chemotherapy, endocrine therapy and combination therapy with targeted agents.
  • Understand how to support patients with adherence to treatment and the important role of the multidisciplinary team in this process.

Clinical Spotlight

  • Can we define the optimal treatment sequence for patients with HR+/HER2- advanced breast cancer? Focus on current clinical data and outstanding challenges.
  • Can we differentiate between the various CDK4/6 inhibitors to ensure they are being used in the right patient at the right time? Focus on efficacy, tolerability, biomarkers and prognostic factors.
  • Can we further optimize patient adherence to treatment? Focus on management strategies and the importance of the multidisciplinary team.

The Expert Panel

Prof. Harbeck

Prof. Di Leo

Prof. Guarneri

Prof. Bidard

Professor Harbeck

Nadia Harbeck, MD, PhD, is Head of the Breast Center and holds the Chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005 to 2009, she was an Assistant Professor and Head of Conservative Senology at TUM and from 2009 to 2011, she was Head of the Breast Center at the University of Cologne, Germany.

Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is Scientific Director of the West German Study Group (www.wsg-online.com). From 2009 to 2015, she served on the executive board of the EORTC as the Chair of the translational research division. Professor Harbeck is Principal Investigator or Steering Committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com).

Professor Harbeck has authored more than 450 papers in peer-reviewed journals (cumulative impact factor > 2000; h-index 67) and is coordinating Editor-in-Chief of Breast Care (Karger Publishers). For her clinical translational research, she has received numerous awards, including the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest-ranking abstract submitted. She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen).

Disclosures: Honoraria for lectures and consulting from Lilly, Novartis and Pfizer.

Professor Di Leo

Angelo Di Leo is currently Head of the Sandro Pitigliani Medical Oncology Unit and Chair of the Department of Oncology at the Hospital of Prato, Istituto Toscano Tumori, Italy, a position he took up in September 2003.

After graduating in medicine and surgery at the University of Palermo, Italy in 1988, he received his postgraduate diploma in medical oncology from the University of Pavia, Italy in 1992, and in 1996 received his European certification in medical oncology.

Professor Di Leo trained at the National Cancer Institute in Milan, Italy, where he worked for 7 years until 1996. From 1996 to 2003, he worked at the Chemotherapy Unit of the Jules Bordet Institute in Brussels, Belgium, where in 1997 he was appointed senior staff member and medical director of the Breast European Adjuvant Studies Team.

Professor Di Leo’s main research interest is breast cancer, and he has coordinated a number of international, pivotal phase III trials in new adjuvant therapies. He is also heavily involved in the evaluation of molecular markers with potential predictive value for breast cancer.

The author of many peer-reviewed articles, Professor Di Leo has lectured extensively at national and international meetings. He is a member of the Early Breast Cancer Trialists’ Cooperative Group Steering Committee, the Breast International Group Executive Board, and Chair of the Biological Protocol Working Group (BPWG) – IBCSG. He has also served on the American Society of Clinical Oncology (ASCO) grants selection committee (2006–2009), the ASCO Education Committee (2012–2014), and the Scientific Advisory Council of the Susan G. Komen for the Cure® (2010–2016).

Disclosures: Advisory role for AstraZeneca, Bayer, Celgene, Daichii-Sankyo, Ipsen, Lilly, Novartis, Pfizer, Puma Biotechnology and Roche. Lecture fees for AstraZeneca, Eisai, Genomic Health, Novartis, Pfizer, Pierre Fabre and Roche.

Professor Guarneri

Valentina Guarneri is Associate Professor of Oncology at the University of Padova and head of the Translational Research and Innovative Therapy Unit at the Division of Medical Oncology 2, Istituto Oncologico Veneto. She is Vice-director of the Specialty Programme in Medical Oncology and a past member of the Research Committee of the Italian Ministry of Health. Her research interests are clinical and translational research for breast cancer patients.

She is a member of the ESMO Fellowship and Award Committee, and the Oncology Pro Working Group, and was a long-standing member of the ESMO Young Oncologists Committee (YOC). She is also a founder member of the Women for Oncology Italy initiative (a national spin-off of the ESMO initiative). She is on the editorial review board of several International journals, including The Lancet Oncology, Annals of Oncology, Clinical Cancer Research, The Oncologist and Clinical Breast Cancer.

Disclosures: Speaker bureau for Astra Zeneca, Eli Lilly and Novartis. Advisory boards for Eli Lilly. Institutional Research grants from Roche.

Professor Bidard

François-Clément Bidard is a Medical Oncologist at Institut Curie (Paris and Saint-Cloud, France) and Professor of Medicine at Versailles Saint Quentin/Paris Saclay University. His clinical practice is devoted to breast cancer care while his translational research concerns metastasis-associated biomarkers, with a focus on circulating tumour biomarkers and liquid biopsies in breast cancer and other tumour types.

Professor Bidard is the Principal Investigator of several Phase II and III trials investigating new therapies for breast cancer (including CDK4/6 inhibitors) and the clinical utility of circulating biomarkers. He is part of the Editorial Board of Oncogene and authored more than 100 publications, including publications as first or last author in Lancet Oncol, Sci Transl Med, JNCI and Nat Rev Clin Oncol.

Disclosures: Advisory role for Eli Lilly and Pfizer. Research grant from Novartis and Pfizer. Lecture fees from Novartis and Pfizer.

Download Slides

touchONCOLOGY ESMO 2018 highlights

touchCONGRESS Webinar

Watch Dr Javier Cortés review the most pertinent emerging data for advanced breast cancer presented at ESMO 2018 and their potential impact on everyday clinical practice.

Watch Now

touchCONGRESS Expert Opinions

Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data for advanced breast cancer from ESMO 2018 and their potential implications for optimizing patient outcomes from both global and local perspectives.

Watch Now

Please feedback on this touchCONGRESS Expert Forum on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).